Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
NG-350a by Akamis Bio for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
NG-350a is under clinical development by Akamis Bio and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...
NG-350a by Akamis Bio for Esophageal Cancer: Likelihood of Approval
NG-350a is under clinical development by Akamis Bio and currently in Phase I for Esophageal Cancer. According to GlobalData, Phase...
NG-350a by Akamis Bio for Uterine Cancer: Likelihood of Approval
NG-350a is under clinical development by Akamis Bio and currently in Phase I for Uterine Cancer. According to GlobalData, Phase...
NG-350a by Akamis Bio for Endometrial Cancer: Likelihood of Approval
NG-350a is under clinical development by Akamis Bio and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase...
NG-350a by Akamis Bio for Hepatocellular Carcinoma: Likelihood of Approval
NG-350a is under clinical development by Akamis Bio and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase...
NG-350a by Akamis Bio for Cervical Cancer: Likelihood of Approval
NG-350a is under clinical development by Akamis Bio and currently in Phase I for Cervical Cancer. According to GlobalData, Phase...